Shanghai Fosun Pharmaceutical
TOPIC
 / company

Shanghai Fosun Pharmaceutical

Shanghai Fosun Pharmaceutical
Shanghai Fosun Pharmaceutical
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a unit of one of China’s largest conglomerates Fosun International.
Chairman / President
Wu Yifang
CEO / Managing Director
Wen Deyong
CFO / Finance Director
Gong Ping
Industry
Pharmaceuticals
Website
fosunpharma.com
Headquarters address
Building A, No. 1289 Yishan Road, Shanghai, China
Stock Code
SEHK:2196, SSE:600196
Year founded
1994
US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

China’s private sector

Fosun brings UK particle therapy to mainland China in advanced cancer care push

The US Food and Drug Administration-approved Marie system promises human-centred care, advanced technology and lower costs.

Fosun Pharmaceutical says the Marie system could reduce total treatment costs by 50 per cent compared with existing therapies. Photo: Daniel Ren
Greater Bay Area

Unmet healthcare demand in Asia presents Chinese hospitals with opportunities

Fosun Health is targeting medical tourists from South Asia, Southeast Asia and the Middle East, CEO Frank Hu Hang says.

China-Africa relations

China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects

Move to manufacture insulin locally is set against forecast of nearly 55 million Type 2 diabetes cases in sub-Saharan Africa by 2045.

videocam
Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Illustration: Henry Wong
Fosun Group

Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms about selling them the rights to an experimental cancer drug.

Robotics

Hong Kong surgical robot start-up Cornerstone takes aim at da Vinci

Company aims to raise US$70 million to develop its systems, which it claims rival the market-leading da Vinci units at lower cost.

Health in China

Chinese pharmaceutical companies look abroad for growth markets

Shanghai Henlius struck a deal in Saudi Arabia while XtalPi signed a partnership with Sinar Mas Multiartha in Indonesia.

Fosun’s Shanghai Henlius, Tecent-backed XtalPi ink partnership deals with Asian partners. Photo: Shanghai Henlius
Hong Kong stock market

Shanghai biotech firm’s shares soar after Fosun’s US$690 million buyout offer

Henlius joins a wave of companies that have left Hong Kong’s stock market this year, either through privatisation or voluntary delisting having found themselves undervalued.

videocam
Phosun Pharma will pay a premium of 36.7 per cent over Monday’s closing price of HK$18 for Henlius. Photo: Reuters
Shenzhen

Chinese drugs giant, Shenzhen team up to invest in city’s biomedical start-ups

Fosun Pharma will team up with Shenzhen’s government to raise a 5-billion yuan (US$700 million) healthcare fund to invest in start-ups and innovations in cellular biology, genetics and other fields related to biomedicine.

videocam
Medicine

Fosun Pharma to deliver China-made surgical robots in key medical milestone

The Fosun Group is looking to make another major leap in the healthcare industry as it prepares to deliver locally-made surgical robots to hospitals.

videocam
China's border reopening

Shanghai Fosun sees mainland demand for Omicron-focused BioNTech shot in Hong Kong

Long queues of mainland Chinese nationals looking to receive the mRNA vaccine have been seen outside Hong Kong clinics following a re-opening of the border.

7
Mainlanders are rushing to Hong Kong for mRNA vaccine. Photo: Reuters
Medicine

Fosun mulls sale of Indian drug maker Gland valued at US$3.6 billion

A sale of Hyderabad-based Gland, which specialises in injectable drugs such as antibiotics, oncology and cardiology treatments, will help Fosun raise cash and shore up its balance sheet.

Fosun Pharma is in talks with prospective buyers to sell its stake in India’s Gland Pharma. Photo: Reuters
Banking & finance

Fosun sells assets amid credit downgrades, liquidity pressure

Fosun International has sold some of its peripheral assets to raise almost US$100 million in cash in recent weeks, as credit rating cuts heighten concerns about the conglomerate’s financial strength.

Coronavirus China

Home-grown vaccine back on the agenda, China energises ‘scientific’ strategy

Remarks by Vice-Premier Liu He suggest vaccine development remains on the agenda for China, with clinical trials of a home-grown Omicron jab having started in Zhejiang.

videocam
27
Advertisement
Advertisement
Advertisement
Fosun Group

Fosun sees profit rise, set to make generic Pfizer, Merck Covid-19 pills

Shanghai Fosun Pharmaceutical Group is looking into which of its existing plants can be used to manufacture generic versions of Pfizer’s nirmatrelvir, which is sold under the Paxlovid brand name, and Merck’s molnupiravir.

videocam
A laboratory manufacturing Pfizer’s Paxlovid in Freiburg, Germany. Fosun Pharma is also eligible to produce and supply the raw ingredients for the drug, which is called nirmatrelvir. Photo: AFP
Medicine

Five Chinese companies approved to make cheaper version of Pfizer’s Covid-19 oral drug

The five Chinese drug makers were among 35 firms to sign non-exclusive sublicensing agreements with the United Nations-backed MPP.

5
Coronavirus vaccine

Fosun Pharma, CanSino favoured as vaccinations, infections boost prospects

Chinese vaccine producers stand to benefit from a move to speed up jabs for the nation’s 1.4 billion population, as well a sudden surge in infections across Asia, adding to a market-beating rally this year, analysts said.

videocam
Fosun Group

Fosun unit Yuyuan sets up US$6.4 billion firm to invest in airlines

Yuyuan’s shares rose by the daily limit of 10 per cent to 13.08 yuan on Thursday amid speculation that its aviation investment company would target Hainan Airlines.

Shops operated by Yuyuan in downtown Shanghai. The new entity will be called Yuyuan Aviation Industry Limited Partnership, according to its filing on Thursday. Photo: Getty Images
Coronavirus pandemic

Fosun unit, BioNTech to form joint venture to make Covid-19 vaccine

The Fosun unit will contribute up to US$100 million of assets including cash and a manufacturing facility, while BioNTech will chip in the licence and know-how.

videocam
56
Shanghai Fosun Pharma is BioNTech’s partner for marketing the company’s Covid-19 vaccine in China, Hong Kong, Taiwan and Macau. Photo: Reuters
Chinese coronavirus vaccines

China seeks to become global vaccine player in wake of Covid-19

The country’s pharmaceutical industry is expanding its production capacity as it gears up to produce 5 billion doses by the end of next year.

videocam
56
Medicine

BioNTech vaccine agent, Fosun Pharma, eyes M&As in global expansion

Fosun Pharma seeks to expand its global sales by tapping merger and acquisition opportunities and launching innovative drugs in more overseas markets, CEO says in an interview.

videocam
Coronavirus pandemic

Exclusive | New BioNTech vaccine batch ready to ship to Hong Kong and Macau, Fosun says

Hong Kong’s health officials last Wednesday abruptly stopped the city’s BioNTech vaccination roll-out on the advice of the vaccine’s supplier, after the scheme’s frontline staff identified 50 defects in the first batch numbered “210102”.

59
People queue for receive the BioNTech jab at the Hiu Kwong Street Sports Centre in Kwun Tong on 16MAR21. Photo: May Tse
Medicine

Sinopharm profit rises, ready to meet China’s 500 million Covid-19 jabs goal

Sinopharm Holding was ready to deliver the Covid-19 vaccines needed to meet Beijing’s target of more than 500 million vaccinations by June this year, its president said.

videocam
Airport workers are inoculated in Nantong in China’s eastern Jiangsu province. Sinopharm conducted a Covid-19 vaccine delivery dry run in December last year to ensure its cold-chain logistics system was safe and efficient. Photo: AP
Coronavirus pandemic

Fosun rushes to ready BioNTech’s Covid-19 vaccine for January use

Shanghai Fosun Pharmaceutical is said to be rushing cold-storage facilities to prepare for possible deployment of BioNTech’s Covid-19 vaccine in China from next month.

videocam
Coronavirus pandemic

China set for 100 million doses of BioNTech vaccine amid overseas roll-out

China is poised to have a mix of foreign and domestic vaccine stocks for its battle against the pandemic.

videocam
32
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement